Literature DB >> 31825543

National treatment trends in human papillomavirus-positive oropharyngeal squamous cell carcinoma.

Kevin Y Zhan1, Sidharth V Puram1, Michael M Li1, Dustin A Silverman1, Amit A Agrawal1, Enver Ozer1, Matthew O Old1, Ricardo L Carrau1, James W Rocco1, Kevin M Higgins2, Danny J Enepekides2, Zain Husain3, Stephen Y Kang1, Antoine Eskander2,4.   

Abstract

BACKGROUND: Human papillomavirus (HPV)-mediated oropharyngeal cancer (OPC) is associated with dramatically improved survival in comparison with HPV-negative OPC and can be successfully treated with surgical and nonsurgical approaches. National treatment trends for OPC were investigated with the National Cancer Data Base (NCDB).
METHODS: The NCDB was reviewed for primary HPV-mediated OPC in 2010-2014. Multivariable regression was used to identify predictors of both nonsurgical therapy and receipt of adjuvant chemoradiation (CRT).
RESULTS: There were 13,363 patients identified with a median age at diagnosis of 58 years. The incidence of triple-modality treatment (surgery with adjuvant chemotherapy) decreased from 23.7% in 2010 to 16.9% in 2014 (R2  = 0.96), whereas the incidence of nonsurgical treatment increased from 63.9% to 68.7% (R2  = 0.89). Hospitals in the top treatment volume quartile (quartile 1 [Q1]; n = 29) had a lower rate of positive margins (16.3%) than bottom-quartile centers (n = 741; rate of positive margins, 36.4%; P < .001); Q1 hospitals used surgical therapy significantly more. Independent predictors of nonsurgical therapy included older age, advanced disease, lower hospital volume, and living closer to the hospital or outside the Pacific United States. In surgically treated patients, younger age, lower hospital volume, nodal disease, positive surgical margins, and extranodal extension (ENE) also predicted more adjuvant CRT use.
CONCLUSIONS: The use of upfront surgical treatment decreased from 2010 to 2014. Hospital volume shows a strong, inverse correlation with the rate of positive surgical margins. The upfront treatment strategy is predicted not only by staging but also by patient-, geographic-, and hospital-specific factors. Lower hospital volume remains independently associated with increased triple-modality therapy after adjustments for positive margins, ENE, and pathologic staging.
© 2019 American Cancer Society.

Entities:  

Keywords:  National Cancer Data Base (NCDB); chemoradiation; de-escalation; human papillomavirus; oropharyngeal cancer; robotic surgery; squamous cell carcinoma; transoral surgery; treatment toxicities; treatment trends

Year:  2019        PMID: 31825543     DOI: 10.1002/cncr.32654

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Time to Surgery and Survival in Head and Neck Cancer.

Authors:  Chandler J Rygalski; Songzhu Zhao; Antoine Eskander; Kevin Y Zhan; Edmund A Mroz; Guy Brock; Dustin A Silverman; Dukagjin Blakaj; Marcelo R Bonomi; Ricardo L Carrau; Matthew O Old; James W Rocco; Nolan B Seim; Sidharth V Puram; Stephen Y Kang
Journal:  Ann Surg Oncol       Date:  2020-11-13       Impact factor: 5.344

2.  Perioperative Mortality Risk in Patients Undergoing Transoral Robotic Surgery for T1-T2 Oropharyngeal Squamous Cell Carcinoma: A National Cancer Database Study.

Authors:  Joel C Davies; Zain Husain; Terry A Day; Evan M Graboyes; Antoine Eskander
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

Review 3.  The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications.

Authors:  Steven F Powell; Lexi Vu; William C Spanos; Dohun Pyeon
Journal:  Cancers (Basel)       Date:  2021-10-17       Impact factor: 6.575

4.  [De-escalation of adjuvant radiotherapy after transoral surgery of HPV-associated oropharyngeal cancer: results of the E3311 trial].

Authors:  Alexander Rühle; Nils H Nicolay
Journal:  Strahlenther Onkol       Date:  2022-02-08       Impact factor: 3.621

5.  Proteome and phosphoproteome signatures of recurrence for HPV+ head and neck squamous cell carcinoma.

Authors:  Tomonori Kaneko; Peter Y F Zeng; Xuguang Liu; Rober Abdo; John W Barrett; Qi Zhang; Anthony C Nichols; Shawn Shun-Cheng Li
Journal:  Commun Med (Lond)       Date:  2022-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.